Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-01-25
2011-01-25
Rawlings, Stephen L (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S138100, C424S155100, C424S174100, C435S375000, C530S387300, C530S387700, C530S388800
Reexamination Certificate
active
07875278
ABSTRACT:
The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
REFERENCES:
patent: 5036003 (1991-07-01), Olander et al.
patent: 5153118 (1992-10-01), Wright, Jr. et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5227471 (1993-07-01), Wright, Jr.
patent: 5453359 (1995-09-01), Gargan et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5538866 (1996-07-01), Israeli et al.
patent: 5643786 (1997-07-01), Cohen et al.
patent: 5773292 (1998-06-01), Bander
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6107090 (2000-08-01), Bander
patent: 6136311 (2000-10-01), Bander
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6194152 (2001-02-01), Laus et al.
patent: 7105159 (2006-09-01), Israeli et al.
patent: 2003/0003101 (2003-01-01), Bander
patent: 2004/0033229 (2004-02-01), Maddon et al.
patent: 2004/0110704 (2004-06-01), Yamane et al.
patent: 2004/0132140 (2004-07-01), Satoh et al.
patent: 2006/0275212 (2006-12-01), Bander
patent: 2250141 (1997-10-01), None
patent: 0228243 (1987-07-01), None
patent: 1176195 (2002-01-01), None
patent: WO-94/02156 (1994-02-01), None
patent: WO-94/09820 (1994-05-01), None
patent: WO-96/08570 (1996-03-01), None
patent: WO-96/26272 (1996-08-01), None
patent: WO-96/39185 (1996-12-01), None
patent: WO-97/35616 (1997-10-01), None
patent: WO-98/03873 (1998-01-01), None
patent: WO-99/47554 (1999-09-01), None
patent: WO-01/09192 (2001-02-01), None
patent: WO-02/069907 (2002-09-01), None
patent: WO-03/034903 (2003-05-01), None
patent: WO-03/035835 (2003-05-01), None
patent: WO-03/064606 (2003-08-01), None
US 6,290,956, 09/2001, Bander (withdrawn)
Niwa et al. (Clin Cancer Res. Sep. 15, 2004;10(18 Pt 1):6248-55).
Yamane-Ohnuki et al. (Biotechnol Bioeng. Sep. 5, 2004;87(5):614-22).
Shields et al. (J Biol Chem. Jul. 26, 2002;277(30):26733-40).
Shinkawa et al. (J Biol Chem. Jul. 31, 2003;278(5):3466-73).
Davies et al. (Biotechnol Bioeng. Aug. 20, 2001;74(4):288-94).
Murphy, Gerald P. et al., “Isolation and Characterization of Monoclonal Antibodies Specific for the Extracellular Domain of Prostate Specific Membrane Antigen,”The Journal of Urology, vol. 160:2396-2401 (1998).
Shinkawa, Toyohide et al., “The Absence of Fucose but Not the Presence of Galactose or BisectingN-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity,”The Journal of Biological Chemistry, vol. 278(5):3466-3473 (2003).
Yamane-Ohnuki, Naoko et al., “Establishment ofFUT8Knockout Chinese Hamster Ovary Cells: An Ideal Host Cell Line for Producing Completely Defucosylated Antibodies With Enhanced Antibody-Dependent Cellular Cytotoxicity,”Biotechnology and Bioengineering, vol. 87(5):614-622 (2004).
Zhu, Lei et al., “Production of human monoclonal antibody in eggs of chimeric chickens,”Nature Biotechnology, vol. 23(9):1159-1169 (2005).
Bander, Neil H. et al., “Phase I Trial of177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer,”Journal of Clinical Oncology, vol. 23(23):4591-4601 (2005).
Beutler, Hans-Otto, “L-Glutamate, Colorimetric Method with Glutamate Dehydrogenase and Diaphorase,” Methods of Enzymatic Analysis, 3rd Edition, Bergmeyer, H.U. ed., vol. VIII, pp. 369-376, VCH Publishers (UK) Ltd., Cambridge, UK (1985).
Brüggermann, Marianne et al., “Strategies for expressing human antibodies repertoires in transgenic mice,”Immunology, Today, vol. 17(8):391-396 (1996).
Caldas, Cristina et al., “Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen,”Molecular Immunology, vol. 39:941-952 (2003).
Carter, Ruth E. et al., “Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase,”Proc. Natl. Acad. Sci. USA, vol. 93:749-753 (1996).
Chang, Sam S. et al., “Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neuvasculature,”Cancer Research, vol. 59:3192-3198 (1999).
Chang, Sam S. et al., “Prostate-specific Membrane Antigen Is Produced in Tumor-associated Neovasculature,”Clinical Cancer Research, vol. 5:2674-2681 (1999).
Chien, Nadine C. et al., “Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism,”Proc. Natl. Acad. Sci. USA, vol. 86:5532-5536 (1989).
Curnow, Randall T., “Clinical experience with CD64-directed immunotherapy. An overview,”Cancer Immunol. Immunother., vol. 45:210-215 (1997).
Donovan, Gerald P. et al., “Antibody and Vaccine Therapies Targeting Prostate Specific Membrane Antigen (PSMA),”Proceedings of the American Association for Cancer Research, vol. 42:818, No. 4389 (2001).
Fernández, I.M. et al., “Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines,”Vaccine, vol. 16(16):1531-1536 (1998).
Fernández, I.M. et al., “Influence of Epitope Polarity and Adjuvants on the Immunogenicity and Efficiacy of a Synthetic Peptide Vaccine against Semliki Forest Virus,”Journal of Virology, vol. 67(10):5843-5848 (1993).
Giusti, Angela M. et al., “Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region,”Proc. Natl. Acad. Sci. USA, vol. 84:2926-2930 (1987).
Gong, Michael C. et al., “Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers,”Cancer and Metastasis Reviews, vol. 18:483-490 (1999).
Green, Larry L., “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies,”Journal of Immunological Methods, vol. 231:11-23 (1999).
Greenspan, Neil S. et al., “Defining epitopes: It's not easy as it seems,”Nature Biotechnology, vol. 17:936-937 (1999).
Güssow, Detlef et al., “Humanization of Monoclonal Antibodies,” Methods in Enzymology, vol. 203, Molecular Design and Modeling Concepts and Applications, Part B, Antibodies and Antigens, Nucleic Acids, Polysaccharides, and Drugs, John J. Langone, Ed., Academic Press, Inc., San Diego, Chpt. 5, pp. 99-121 (1991).
Hamilton, A. et al., “A novel humanized antibody against Prostate Specific Membrane Antigen (PSMA) for in vivo targeting and therapy,”Proceedings of the American Association for Cancer Research 89th Annual Meeting, New Orleans, Louisiana, USA, vol. 39, No. 2997 (1989).
Heston, Warren D.W., “Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase,”Urology, vol. 49(Suppl. 3A):104-112 (1997).
Holmes, Eric H. et al., “Analysis of Glycosylation of Prostate-Specific Membrane Antigen Derived From LNCaP Cells, Prostatic Carcinoma Tumors, and Serum From Prostate Cancer Patients,”The Prostate Supplement, vol. 7:25-29 (1996).
Holmes, Eric H. et al., “Development and Characterization of Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-Specific Membrane Antigen,”Cancer Biotherapy&Radiopharmaceuticals, vol. 13(1):55, No. 12 (1998).
Horoszewicz
Albanese Jenny
Cardarelli Josephine M.
Passmore David B.
Zhu Lei
DiGiorgio, Esq. Jeanne M.
Lahive & Cockfield LLP
Medarex Inc.
Rawlings Stephen L
Remillard, Esq. Jane E.
LandOfFree
Monoclonal antibodies against prostate specific membrane... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against prostate specific membrane..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against prostate specific membrane... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683293